Per journal article in hernia (2021) titled, ¿safety and efficacy in inguinal hernia repair: a retrospective study comparing trepp, tep and lichtenstein (settle).¿ featured was a retrospective cohort study, 300 patients of which 58 (19.3%) underwent trepp, 190 (63.3%) tep and 52 (17.3%) lichtenstein with bard/davol onflex, non-bard/davol parietex, non-bard/davol biomesh respectively over a period of 7 months from march to september 2019.The primary outcome of this study was inguinal hernia recurrence rate within 1 year after surgery.Secondary objectives were chronic post-operative inguinal pain (cpip) lasting more than 6 months, (major) complication rates and operating time.The following complications were observed from 58 patients treated with onflex mesh during trepp inguinal hernia repair: recurrence 2 (1.7%) patients; chronic pain (>6 months) 1 (1.7%) patient; hematoma (surgical evacuation) 5 (8.6%) patients & wound infection 4 (6.9%) patients.Information is presented without patient/case specific details.
|
Based on the information provided, no conclusions can be made.The information obtained is limited to the article.As reported, post-implant of the onflex mesh, patients developed hernia recurrence, wound infection, chronic pain & hematoma.Hematoma, pain, infection, and recurrence of the hernia are known inherent risks of surgery/use of the device and are listed in the adverse reactions section of the instructions-for-use, supplied with the device, as possible complications.Regarding infection the ifu states, "if an infection develops, treat the infection aggressively.Consideration should be given regarding the need to remove the mesh.An unresolved infection may require removal of the mesh." no lot number has been provided; therefore, a review of the manufacturing records is not possible.Note, the date of event is provided as an estimate based on the information provided.Not returned.
|